XML 34 R14.htm IDEA: XBRL DOCUMENT
v3.20.4

Major Customers and Concentration of Credit Risk | 12 Months Ended
--- | ---
Dec. 31, 2020
Risks and Uncertainties [Abstract] |
Major Customers and Concentration of Credit Risk | Major Customers and Concentration of Credit Risk
Customer | 2020 Revenue |  | % of Total Revenue |  | 2019 Revenue |  | % of Total Revenue |  | 2018 Revenue |  | % of Total Revenue
ApolloBio | $ | — |  |  | — | % |  | $ | — |  |  | — | % |  | $ | 23,000,000 |  |  | 75 | %
AstraZeneca | 170,587 |  |  | 2 |  |  | 3,194,877 |  |  | 78 |  |  | 6,850,424 |  |  | 23 |
Advaccine | 5,000,000 |  |  | 68 |  |  | — |  |  | — |  |  | — |  |  | — |
Plumbline Life Sciences, Inc. | 1,370,396 |  |  | 18 |  |  | — |  |  | — |  |  | — |  |  | — |
All other, including affiliated entities | 870,237 |  |  | 12 |  |  | 917,053 |  |  | 22 |  |  | 631,473 |  |  | 2 |
Total revenue | $ | 7,411,220 |  |  | 100 | % | 1 | $ | 4,111,930 |  |  | 100 | % |  | $ | 30,481,897 |  |  | 100 | %
During the years ended December 31, 2020, 2019 and 2018, the Company recognized revenue from various license and other agreements. As of December 31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. As of December 31, 2019, $469,000, or 67%, and $161,000, or 23%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration